Potential use of the human amniotic membrane as a scaffold in human articular cartilage repair
View/ Open
Use this link to cite
http://hdl.handle.net/2183/14686Collections
- GI-TCMR - Artigos [123]
- INIBIC-TCMR - Artigos [102]
- INIBIC- REUMA - Artigos [182]
Metadata
Show full item recordTitle
Potential use of the human amniotic membrane as a scaffold in human articular cartilage repairAuthor(s)
Date
2010-04-13Citation
Díaz-Prado S, Rendal-Vázquez ME, Muíños-López E, Hermida-Gómez T, Rodríguez-Cabarcos M, Fuentes-Boquete I, et al. Potential use of the human amniotic membrane as a scaffold in human articular cartilage repair. Cell Tissue Bank. 2010;11:183-195.
Abstract
[Abstract] The human amniotic membrane (HAM) is an abundant and readily obtained tissue that may be an important source of scaffold for transplanted chondrocytes in cartilage regeneration in vivo. To evaluate the potential use of cryopreserved HAMs as a support system for human chondrocytes in human articular cartilage repair. Chondrocytes were isolated from human articular cartilage, cultured and grown on the chorionic basement membrane side of HAMs. HAMs with chondrocytes were then used in 44 in vitro human osteoarthritis cartilage repair trials. Repair was evaluated at 4, 8 and 16 weeks by histological analysis. Chondrocytes cultured on the HAM revealed that cells grew on the chorionic basement membrane layer, but not on the epithelial side. Chondrocytes grown on the chorionic side of the HAM express type II collagen but not type I, indicating that after being in culture for 3–4 weeks they had not de-differentiated into fibroblasts. In vitro repair experiments showed formation on OA cartilage of new tissue expressing type II collagen. Integration of the new tissue with OA cartilage was excellent. The results indicate that cryopreserved HAMs can be used to support chondrocyte proliferation for transplantation therapy to repair OA cartilage.
Keywords
Amniotic membrane
Chondrocytes
Cartilage
Osteoarthritis
Cell therapy
Chondrocytes
Cartilage
Osteoarthritis
Cell therapy
Editor version
Rights
The final publication is avaliable at link.spinger.com